Cargando…

Cost-Effectiveness of Waiving Coinsurance for Follow-Up Colonoscopy after a Positive Stool-Based Colorectal Screening Test in a Medicare Population

Commercial insurance covers a follow-up colonoscopy after a positive colorectal cancer–screening test with no patient cost-sharing. Instituting a similar policy for Medicare beneficiaries may increase screening adherence and improve outcomes. The cost-effectiveness of stool-based colorectal cancer s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fendrick, A. Mark, Lieberman, David, Vahdat, Vahab, Chen, Jing Voon, Ozbay, A. Burak, Limburg, Paul J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for Cancer Research 2022
Materias:	Research Brief
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9530644/ https://www.ncbi.nlm.nih.gov/pubmed/35768200 http://dx.doi.org/10.1158/1940-6207.CAPR-22-0153

Ejemplares similares

Impact of Eliminating Cost-Sharing by Medicare Beneficiaries for Follow-Up Colonoscopy After a Positive Stool-based Colorectal Cancer Screening Test
por: Fendrick, A. Mark, et al.
Publicado: (2023)

Comparison of Simulated Outcomes Between Stool- and Blood-Based Colorectal Cancer Screening Tests
por: Fendrick, A. Mark, et al.
Publicado: (2023)

Impact of Patient Adherence to Stool-Based Colorectal Cancer Screening and Colonoscopy Following a Positive Test on Clinical Outcomes
por: Fendrick, A. Mark, et al.
Publicado: (2021)

Life-years gained resulting from screening colonoscopy compared with follow-up colonoscopy after a positive stool-based colorectal screening test
por: Mark Fendrick, A., et al.
Publicado: (2022)

Out-of-Pocket Costs for Colonoscopy After Noninvasive Colorectal Cancer Screening Among US Adults With Commercial and Medicare Insurance
por: Fendrick, A. Mark, et al.
Publicado: (2021)

Medicare Second Surgical Opinion Programs: The Effect of Waiving Cost-Sharing
por: Friedlob, Alan S.
Publicado: (1982)

Impact of screening and follow‐up colonoscopy adenoma sensitivity on colorectal cancer screening outcomes in the CRC‐AIM microsimulation model
por: Fisher, Deborah A., et al.
Publicado: (2020)

Cost-Effectiveness of Outreach Strategies for Stool-Based Colorectal Cancer Screening in a Medicaid Population
por: Karlitz, Jordan J., et al.
Publicado: (2022)

Estimating the impact of differential adherence on the comparative effectiveness of stool-based colorectal cancer screening using the CRC-AIM microsimulation model
por: Piscitello, Andrew, et al.
Publicado: (2020)

Association of Drug Rebates and Competition With Out-of-Pocket Coinsurance in Medicare Part D, 2014 to 2018
por: Lakdawalla, Darius, et al.
Publicado: (2021)

Comparison of Screening Colonoscopy Rates After Positive Noninvasive Testing for Colorectal Cancer in States With and Without Cost-Sharing
por: Barthold, Douglas, et al.
Publicado: (2022)

Calibration and Validation of the Colorectal Cancer and Adenoma Incidence and Mortality (CRC-AIM) Microsimulation Model Using Deep Neural Networks
por: Vahdat, Vahab, et al.
Publicado: (2023)

Assessment of Behavioral Health Services Use Among Low-Income Medicare Beneficiaries After Reductions in Coinsurance Fees
por: Fung, Vicki, et al.
Publicado: (2020)

Cross-sectional adherence with the multi-target stool DNA test for colorectal cancer screening in a medicaid population
por: Miller-Wilson, Lesley-Ann, et al.
Publicado: (2022)

Cross-sectional adherence with the multi-target stool DNA test for colorectal cancer screening in a large, nationally insured cohort
por: Miller-Wilson, Lesley-Ann, et al.
Publicado: (2021)

Effect on Drug Utilization and Expenditures of a Cost-Share Change From Copayment to Coinsurance
por: Klepser, Donald G., et al.
Publicado: (2007)

Medicare cost of colorectal cancer screening: CT colonography vs. optical colonoscopy
por: Pyenson, Bruce, et al.
Publicado: (2015)

The Impact of Waived Cost-Sharing Policy on COVID-19 Daily Testing and Deaths
por: Almuqarrab, Ahmed, et al.
Publicado: (2022)

Cost-effectiveness of a multitarget stool DNA test for colorectal cancer screening of Medicare beneficiaries
por: Naber, Steffie K., et al.
Publicado: (2019)

Follow-up colonoscopy after an abnormal stool-based colorectal cancer screening result: analysis of steps in the colonoscopy completion process
por: Coronado, Gloria D., et al.
Publicado: (2021)

Waived Consent in Perinatal/Neonatal Research—When Is It Appropriate?
por: Rich, Wade D., et al.
Publicado: (2019)

Scientific Rationale for Waiving Clinical Efficacy Testing of Biosimilars
por: Niazi, Sarfaraz
Publicado: (2022)

The effect of increasing the coinsurance rate on outpatient utilization of healthcare services in South Korea
por: Lee, Hyo Jung, et al.
Publicado: (2017)

Impact of the 2014 coinsurance rate revision for the elderly on healthcare resource utilization in Japan
por: Nishi, Takumi, et al.
Publicado: (2021)

Impact of Coinsurance Reduction Policy on Healthcare Utilization Among Children Under 15
por: Park, Minah, et al.
Publicado: (2023)

What do ‘false-positive’ stool tests really mean? Data from the New Hampshire colonoscopy registry
por: Butterly, Lynn F., et al.
Publicado: (2023)

Multitarget Stool DNA Screening in Clinical Practice: High Positive Predictive Value for Colorectal Neoplasia Regardless of Exposure to Previous Colonoscopy
por: Eckmann, Jason D., et al.
Publicado: (2020)

Impact of COVID-19 on prevalence of community pharmacies as CLIA-Waived facilities
por: Klepser, Nicklas S., et al.
Publicado: (2021)

Parental Perspectives on a Trial Using Waived Informed Consent at Birth
por: Katheria, Anup, et al.
Publicado: (2023)

The Utilization and Costs of Grade D USPSTF Services in Medicare, 2007–2016
por: Oronce, Carlos Irwin A., et al.
Publicado: (2021)

Costs and repeat rates associated with colonoscopy observed in medical claims for commercial and Medicare populations
por: Pyenson, Bruce, et al.
Publicado: (2014)

Waiving in vivo studies for monoclonal antibody biosimilar development: National and global challenges
por: Chapman, Kathryn, et al.
Publicado: (2016)

Trends in the Cost and Utilization of Omalizumab in the Medicare Population: 2013-2017
por: Cheraghlou, Shayan, et al.
Publicado: (2022)

Geographic Variations in Incremental Costs of Heart Disease Among Medicare Beneficiaries, by Type of Service, 2012
por: Wakim, Rita, et al.
Publicado: (2016)

Multitarget stool DNA tests increases colorectal cancer screening among previously noncompliant Medicare patients
por: Prince, Mark, et al.
Publicado: (2017)

Medicare Must Provide Additional Cost and Access Information to Enhance Decision Making Around Trade Offs Between Medicare Advantage and Medigap
por: Grabert, Lisa M.
Publicado: (2022)

Alaska Native Patient and Provider Perspectives on the Multitarget Stool DNA Test Compared With Colonoscopy for Colorectal Cancer Screening
por: Redwood, Diana G., et al.
Publicado: (2019)

Uptake and cost of biosimilar filgrastim among Medicare and Medicaid populations in 2015-2018
por: Qian, Jingjing
Publicado: (2021)

Ability of community pharmacists to independently perform CLIA-waived testing – A multistate legal review
por: Doucette, Joseph, et al.
Publicado: (2021)

Colonoscopy colorectal cancer screening: Cost-effectiveness in Thailand
por: Joob, Beuy, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_41ijjtorqpf582m2ctiun6tupc